ControlRad™ Announces Activities at NASS, OTA and TCT 2019 Annual Meetings
ATLANTA–(BUSINESS WIRE)–ControlRad, Inc., a privately held medical technology company focused on dramatically reducing unnecessary radiation exposure during fluoroscopically guided procedures, today announced company-sponsored events for ControlRad Trace at the annual meetings of NASS (Chicago), OTA (Denver) and TCT (San Francisco), all starting Sept. 25.
ControlRad Trace received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in May and is the only technology that can be integrated into existing mobile C-arms to reduce radiation in any fluoroscopic imaging procedure.
North American Spine Society (NASS) Annual Meeting – Sept. 25-28
ControlRad is hosting an educational event, “Dramatically Reducing C-arm Radiation Exposure,” on Wednesday, September 25, from 5:30-7:30 p.m. The featured guest lecturer will be Dr. Andrew Cappuccino of Buffalo Spine Surgery, who will share his experience as a minimally invasive spine surgeon and cancer survivor. To RSVP for the event, email events@controlrad.com.
ControlRad will also be exhibiting in booth 4033.
Orthopaedic Trauma Association (OTA) Annual Meeting – Sept. 25-28
ControlRad will be exhibiting in booth 424.
Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium – Sept. 25-29
ControlRad will be offering hands-on experience with ControlRad Trace in booth 1534.
About ControlRad Trace
Fluoroscopically guided procedures (FGP) with C-arms have allowed for major advances in treating countless diseases, however they expose patients and medical staff to ionizing radiation, which may increase a person’s lifetime risk of developing cancer.1 ControlRad Trace is the only technology that can be integrated into existing mobile C-arms to reduce radiation in any fluoroscopic imaging procedure. With its proprietary semi-transparent filter, tablet and image processing technology, the ControlRad Trace solution can be retrofitted on existing C-arms, reducing the barrier to adopting the technology. The ControlRad Trace reduces unnecessary radiation up to 89%,2 protecting patients and medical staff without compromising image quality in the region of interest and overall workflow. The medical staff draws a region of interest (ROI) on a ControlRad tablet, which in real-time optimizes image quality in the ROI while reducing unnecessary radiation in the periphery.
About ControlRad
ControlRad is a privately held medical technology company developing innovative products that dramatically reduce the radiation exposure from fluoroscopically guided procedures (FGP) for patients and healthcare professionals. ControlRad’s products are designed to improve safety without compromising image quality or workflow. They include an integrated set of proprietary components, which optimize the X-ray beam to deliver optimal image quality in the clinically relevant region while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Atlanta, Georgia, and has engineering development facilities in Kfar Saba, Israel. For more information, visit www.controlrad.com.
________________________________________
1https://www.fda.gov/radiation-emitting-products/initiative-reduce-unnecessary-radiation-exposure-medical-imaging/white-paper-initiative-reduce-unnecessary-radiation-exposure-medical-imaging
2 Data on file
Contacts
Joni Ramirez
Merryman Communications
joni@merrymancommunications.com
323-532-0746
